Novanex Biosciences is a clinical-stage biotechnology company focused on developing novel therapeutics for sleep-wake cycle disorders, with a particular emphasis on REM sleep behavior disorder (RBD) in neurodegenerative diseases.
Headquartered in Cambridge, Massachusetts, Novanex was founded in 2021 by neuroscientists from Harvard Medical School and Mass General Hospital who recognized the significant unmet need in RBD treatment.
RBD represents one of the most significant unmet needs in neurodegenerative disease treatment:
- No approved therapies: Despite affecting 50+ million people worldwide, no FDA-approved drugs exist for RBD
- Prodromal marker: RBD precedes synucleinopathies by 5-15 years in ~80% of cases
- Injury risk: Patients suffer self-injury and injury to bed partners during dream enactment
| Drug |
Indication |
Mechanism |
Stage |
| NVX-001 |
RBD |
GABA-B receptor modulator |
Preclinical |
| NVX-002 |
RBD/PD |
Selective serotonin receptor targeting |
Discovery |
| NVX-003 |
Insomnia in PD |
Novel orexin receptor modulator |
Discovery |
NVX-001 is a selective GABA-B receptor modulator designed to restore REM sleep atonia without causing significant sedation or tolerance:
- Mechanism: Positive allosteric modulation of GABA-B receptors in the sublaterodorsal nucleus
- Target: Selectively reduce muscle activity during REM sleep while preserving normal sleep architecture
- Advantage: Expected to have better safety profile than clonazepam (current off-label standard)
Novanex utilizes:
- Human iPSC-derived neurons: Modeling brainstem sleep-wake circuits
- Translational biomarkers: Sleep EEG and muscle EMG endpoints
- Genetic screens: Identifying patients who may respond best to GABAergic modulation
- Idiopathic RBD: First-line target (no approved therapies)
- PD-associated RBD: Second indication in Parkinson's disease
- DLB-associated RBD: Dementia with Lewy bodies
- MSA-associated RBD: Multiple system atrophy
Novanex has established collaborations with:
- Michael J. Fox Foundation for RBD biomarker research
- Academic sleep centers for clinical trial execution
- Pharmaceutical companies for potential co-development
- Seed round: $5M (2021)
- Series A: $25M (2023) - led by Foundation for Parkinson's Research
- Grants: MJFF clinical trial design grant (2024)
¶ Competitive Landscape
| Company |
Approach |
Status |
| Off-label |
Clonazepam, Melatonin |
Standard of care |
| Idorsia |
Orexin antagonists |
Approved for insomnia |
| Novanex |
GABA-B modulators |
Preclinical |
| Academic consortia |
Various |
Research |
Novanex positions itself to address the significant unmet need in RBD:
- First-mover advantage: Potentially first company to bring RBD-specific therapy to market
- Companion diagnostics: Developing biomarkers to identify likely responders
- Disease modification: Exploring whether early RBD treatment could slow neurodegeneration